表紙
市場調查報告書

Cathepsin S (EC 3.4.22.27) :開發中產品分析

Cathepsin S (CTSS or EC 3.4.22.27) - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 363132
出版日期 內容資訊 英文 34 Pages
訂單完成後即時交付
價格
Back to Top
Cathepsin S (EC 3.4.22.27) :開發中產品分析 Cathepsin S (CTSS or EC 3.4.22.27) - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 34 Pages
簡介

本報告提供Cathepsin S藥物的開發情形相關資訊,提供您各開發階段,藥物標的,作用機制,給藥途徑及分子類型別分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

Cathepsin S概要

治療藥的開發

Cathepsin S:開發中的產品 - 各開發階段

Cathepsin S:開發中的產品 - 治療範圍別

Cathepsin S:開發中的產品 - 各適應症

Cathepsin S:開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

Cathepsin S:企業開發中的產品

Cathepsin S:治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

Cathepsin S治療藥的開發企業

  • Amura Holdings Limited
  • F. Hoffmann-La Roche Ltd.
  • Fusion Antibodies Limited
  • LEO Pharma A/S
  • Virobay Inc.

Cathepsin S:藥物簡介

Cathepsin S:暫停中的計劃

Cathepsin S:中止開發的產品

Cathepsin S:主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2049TDB

Summary

According to the recently published report 'Cathepsin S (CTSS or EC 3.4.22.27) - Pipeline Review, H2 2019'; Cathepsin S (CTSS or EC 3.4.22.27) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.

Cathepsin S (CTSS or EC 3.4.22.27) - Cathepsin S is a lysosomal enzyme that belongs to the papain family of cysteine proteases. Cathepsin S has a role in itch and pain, or nociception. The nociceptive activity results from cathepsin S functioning as a signaling molecule via activation of protease-activated receptors 2 and 4 members of the G-protein coupled receptor family. Cathepsin S has a physiological role outside the lysosome. Immune cells, including macrophages and microglia, secrete cathepsin S in response to inflammatory mediators including lipopolysaccharides, proinflammatory cytokines and neutrophils.

The report 'Cathepsin S (CTSS or EC 3.4.22.27) - Pipeline Review, H2 2019' outlays comprehensive information on the Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase 0, Preclinical and Discovery stages are 1, 4 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Gastrointestinal, Immunology, Infectious Disease and Metabolic Disorders which include indications Alzheimer's Disease, Autoimmune Disorders, Breast Cancer, Cancer Pain, Chagas Disease (American Trypanosomiasis), Colorectal Cancer, Diabetic Retinopathy, Glioblastoma Multiforme (GBM), Liver Fibrosis, Neuropathic Pain (Neuralgia), Pancreatic Cancer, Primary Biliary Cholangitis (Primary Biliary Cirrhosis) and Prostate Cancer.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Cathepsin S (CTSS or EC 3.4.22.27)
  • The report reviews Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cathepsin S (CTSS or EC 3.4.22.27)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cathepsin S (CTSS or EC 3.4.22.27) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Cathepsin S (CTSS or EC 3.4.22.27) - Overview
  • Cathepsin S (CTSS or EC 3.4.22.27) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Cathepsin S (CTSS or EC 3.4.22.27) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Cathepsin S (CTSS or EC 3.4.22.27) - Companies Involved in Therapeutics Development
  • Evotec SE
  • F. Hoffmann-La Roche Ltd
  • Fusion Antibodies Plc
  • Virobay Inc
  • Cathepsin S (CTSS or EC 3.4.22.27) - Drug Profiles
  • Fsn-0503h - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RO-5461111 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SAR-114137 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit Cathepsin S for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VBY-285 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VBY-50365 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VBY-825 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cathepsin S (CTSS or EC 3.4.22.27) - Dormant Products
  • Cathepsin S (CTSS or EC 3.4.22.27) - Discontinued Products
  • Cathepsin S (CTSS or EC 3.4.22.27) - Product Development Milestones
  • Featured News & Press Releases
  • Jul 27, 2015: NIH helps UC San Diego researchers repurpose Sanofi pain drug for tropical disease
  • Nov 14, 2014: Virobay To Present Data On Two Cathepsin S Inhibitor Programs In Neuropathic Pain And Alzheimer's Disease At The 2014 Society For Neuroscience Annual Meeting
  • Nov 14, 2011: Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy In Bone Cancer Model
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Evotec SE, H2 2019
  • Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
  • Pipeline by Fusion Antibodies Plc, H2 2019
  • Pipeline by Virobay Inc, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top